Optimum Symptomatic Control of Parkinson's Disease with Dopaminergic Therapy

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

• Publication date

  1987-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/S0317167100037926PMID 3676921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085

  2004cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• The on-off phenomenon.

  1989cited by this paper
• A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.

  1988cited by this paper
• [Biochemistry of Parkinson's disease].

  1988cited by this paper
• Dopamine agonists as primary treatment in Parkinson's disease.

  1987cited by this paper
• Low‐dose bromocriptine therapy in Parkinson's disease

  1986cited by this paper
• Long‐term follow‐up of early dopa treatment in Parkinson's disease

  1986cited by this paper
• Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

  1986cited by this paper
• Bromocriptine: long-term low-dose therapy in Parkinson's disease.

  1986cited by this paper
• Combined bromocriptine‐levodopa therapy early in Parkinson's disease

  1985cited by this paper
• Low-dose bromocriptine therapy in Parkinson's disease.

  1985cited by this paper
• Chronic agonist therapy for Parkinson's disease

  1985cited by this paper
• Long‐term experience with pergolide therapy of advanced parkinsonism

  1985cited by this paper
• Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.

  1985cited by this paper
• Initial treatment of parkinsonism with 8‐alpha‐amino‐ergoline

  1985cited by this paper
• A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa

  1985cited by this paper
• Chronic low‐dose levodopa therapy in Parkinson's disease

  1984cited by this paper
• Pergolide in the treatment of Parkinson's disease

  1984cited by this paper
• Dopamine Agonists in Parkinson’s Disease

  1984cited by this paper
• Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment

  1984cited by this paper
• Limitations of Long Term Use of Antiparkinson Drugs

  1984cited by this paper
• Low‐Dose Bromocriptine Therapy in Severe Parkinson's Disease

  1984cited by this paper
• Lisuride and pergolide in Parkinson's disease.

  1983cited by this paper
• Evaluating the evaluations

  1983cited by this paper
• Induction of oral dyskinesias in naive rats by D1 stimulation.

  1983cited by this paper
• Experimental therapeutics of movement disorders.

  1983cited by this paper
• Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.

  1983cited by this paper
• [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].

  1982cited by this paper
• Evidence to support early levodopa therapy in Parkinson disease

  1981cited by this paper
• Sinemet and the treatment of Parkinsonism.

  1981cited by this paper
• Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.

  1981cited by this paper
• Long‐term efficacy of bromocriptine in Parkinson disease

  1980cited by this paper
• Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.

  1979cited by this paper
• Long-term treatment of Parkinson's disease with bromocriptine.

  1979cited by this paper
• Bromocryptine in Levodopa Response-Losing Parkinsonism

  1978cited by this paper
• Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains

  1978cited by this paper
• Brain dopamine receptor stimulation and the relief of parkinsonism: Relationship between bromocriptine and levodopa

  1978cited by this paper
• Chapter 9: Dopaminergic Agonists in the Treatment of Parkinsonism

  1978cited by this paper
• Bromocryptine in levodopa response-losing parkinsonism. A double blind study.

  1978cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Bromocriptine in parkinsonism. A long-term study.

  1978cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.

  1977cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.

  1976cited by this paper
• Treatment of parkinson's disease with bromocriptine.

  1976cited by this paper
• [Treatment of Parkinson's disease with bromocriptine].

  1976cited by this paper
• Memory and Growth in the Superior Temporal Gyri

  1975cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper
• Letter: Zinc and diodoquin in acrodermatitis enteropathica.

  1975cited by this paper
• Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

  1975cited by this paper
• Drugs Five Years Later: Levodopa

  1975cited by this paper
• Bromocriptine in Parkinsonism

  1974cited by this paper
• Letter: Danfa project.

  1974cited by this paper
• Sustained levodopa therapy in parkinsonism.

  1973cited by this paper
• Enhanced response to low doses of levodopa after withdrawal from chronic treatment

  1972cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• Parkinsonism

  1967cited by this paper
• Excretion of Dopamine in Diseases of Basal Ganglia

  1961cited by this paper
• Action of d-Tubocurarine Chloride on Net Flux of Water across Isolated Frog Skin

  1961cited by this paper

• Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson’s Disease

  2022cites this paper
• Dopamine replacement therapy does not restore the ability of Parkinsonian patients to make rapid adjustments in motor strategies according to changing sensorimotor contexts.

  2007cites this paper
• Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6‐OHDA dopamine‐depleted (hemi‐Parkinson analogue) rats

  2001cites this paper
• Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.

  1991cites this paper
• Early Diagnosis and Preventive Therapy in Parkinson’s Disease

  1989cites this paper
• Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?

  1989cites this paper